Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Address: Av. Doutor Cardoso de Melo, 1.184, 17º andar Vila Olimpia São Paulo – SP – Brasil Cep: 04548-004,Brazil
Tel: +55 11 3568-3400
Web: http://www.biogenidec.com.br/
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology leader with products in oncology, neurology and immunology. Biogen Idec is committed to transforming scientific discoveries into advances and health care. The company’s include the discovery, research, development and biomanufacturing of medicine and a global commercial infrastructure.
Biogen Idec pursues the creativity of science with passion and discipline. For over 25 years, the company has grown through the discovery, development and commercialization of innovative products themselves and through strategic alliances.
Scientific excellence that achieves new standards of care drives the company’s work. Currently, more than twenty products are in clinical development to meet a number of important medical needs.
Biogen Idec has affiliates in Brazil, Canada, Australia, Japan and throughout Europe, including the international headquarters in Zug, Switzerland. The company currently employs approximately 3,600 people worldwide.
In Brazil, Biogen Idec is focused on the Multiple Sclerosis market, as an expert company in the disease, and is responsible for organizing World MS Day activities in the country.
Avonex, Tysabri
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and…
GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance…
The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a…
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
The latest news from Brazil, including Pfizer’s plans to vaccinate the entire Brazilian city of Toledo, what the US can learn from Brazil’s successful vaccine campaign, and a new deal…
The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine…
Founded in 1950, EMS is one of the top two domestic pharma companies in Brazil. As a key player in the largest and most populous nation in Latin America, the…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known…
Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.* The OTC…
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The editorial team at Panorama Farmaceutico explain how the COVID-19 pandemic and global trade flow stoppages are impacting the manufacture and supply of medicines within Brazil.* The COVID-19 pandemic…
See our Cookie Privacy Policy Here
